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Abstract 
Background: Endothelial progenitor cells (EPCs) contribute to recanalization of deep vein thrombosis (DVT). This 
study aimed to detect miRNA expression profiles in EPCs from patients with DVT and characterize the role of miRNA 
in EPCs dysfunction.
Methods: EPCs was isolated from DVT patients and control subjects, and miRNA expression profiles were compared 
to screen differential miRNAs. The candidate miRNAs were confirmed by RT-PCR analysis. The targets of miRNA were 
identified by bioinformatics analyses, luciferase reporter assay and gene expression analyses. The apoptosis, migration 
and tube formation of EPCs were examined by flow cytometry, transwell assay and matrigel tube formation assay. A 
rat model of venous thrombosis was established as in vivo model.
Results: We identified miR-483-3p as a candidate miRNA upregulated in EPCs from DVT patients. By using miR-
483-3p agomir and antagomir, we demonstrated that miR-483-3p decreased the migration and tube formation while 
increased the apoptosis of EPCs. Moreover, we identified serum response factor (SRF) as the target of miR-483-3p, and 
showed that SRF knockdown decreased the migration and tube formation while increased the apoptosis of EPCs. In 
addition, miR-483-3p inhibition led to enhanced ability of homing and thrombus resolution of EPCs in rat model of 
venous thrombosis.
Conclusions: miR-483-3p is upregulated in EPCs from DVT patients, and it targets SRF to decrease EPCs migration 
and tube formation and increase apoptosis in vitro, while decrease EPCs homing and thrombus resolution in vivo. 
MiR-483-3p is a potential therapeutic target in DVT treatment.
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Background
Deep vein thrombosis (DVT) occurs when a blood clot 
forms in the deep vein of human body, and is a com-
mon peripheral vascular disease that causes major mor-
bidity and mortality in various medical conditions [1]. 
Moreover, lower and upper extremities DVT cause 
post-thrombotic syndrome (PTS) and pulmonary embo-
lism (PE), which could result in over 15 % death rate in 
the first 3  month after diagnosis [2]. Currently, antico-
agulation therapy is the standard method for DVT, but 
the failure to the removal of existing thrombus and the 
risk of PE hinder the use of the therapy [3]. Therefore, it 
is urgent to develop a safe and efficient therapy for DVT 
treatment.
Endothelial progenitor cells (EPCs), a bone mar-
row-derived circulating progenitor for the endothelial 
lineage, play an important role in pathological and physi-
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recruited into the thrombus during a resolution and 
involved in thrombus recanalization [6–8]. Lower num-
bers of EPCs in the thrombus may result in diminished 
thrombus recanalization and resolution. Therefore, effec-
tive recruitment of EPCs into the thrombus may be a 
problem of clinical significance.
MiRNAs participate in various biological events [9, 10], 
and recent studies suggested that miRNAs are involved 
in EPCs function [11]. The upregulation of miR-107 in 
hypoxia condition led to EPCs differentiation inhibition 
by targeting HIF-1β [12]. miR-130a was involved in the 
regulation of autophagy function in EPCs via targeting 
Runx3 [13]. In addition, our previous studies showed 
that miR-150 and miR-126 contributed to EPCs function 
in vitro and improved thrombus recanalization and reso-
lution in vivo [14, 15].
Here we reported the upregulation of miR-483-3p in 
DVT patients and demonstrated that ectopic expression of 
miR-483-3p attenuated the migration, tube formation and 
increased the apoptosis of EPCs via SRF in vitro. Moreo-
ver, we tested the efficacy of miR-483-3p modified EPCs in 
the treatment of vein thrombosis using a rat model.
Methods
Subjects
Eighty milliliter of peripheral blood were collected from 
DVT patients (n  =  3) and control subjects (n  =  3) at 
the Second Affiliated Hospital of Soochow University, 
Suzhou, China. The included DVT patients were con-
firmed by Color doppler ultrasound and lower extremity 
angiography without a history of hypertension, diabetes 
mellitus and other chronic diseases. Patients and healthy 
controls were matched by the age, gender and other risk 
factors (Table  1). The protocols were approved by the 
Institutional Review Board of the Second Affiliated Hos-
pital of Soochow University and written informed con-
sent was obtained from each participant.
Isolation of EPCs
EPCs were isolated and characterized according to pre-
vious methods [16, 17]. Peripheral blood mononuclear 
cells (PBMCs) were isolated using Ficoll-Isopaque Plus 
(Histopaque-1077; Sigma, MO, USA) gradient centrifu-
gation method. The PBMCs were seeded onto fibronec-
tin-coated cell culture flask, cultured in endothelial basal 
medium-2 (EBM-2; Lonza, MD, USA) supplemented 
with 20  % fetal bovine serum (FBS), vascular endothe-
lial growth factor (VEGF; R&D Systems, MN, USA), 
human recombinant long insulin-like growth factor-1 
(R3-IGF), ascorbic acid, and hydrocortisone and main-
tained at 37 °C, 5 % CO2 incubator. Medium change was 
performed after 4 days culture and early EPCs developed 
an elongated spindle-shaped morphology after 7  days 
culture. EPCs were characterized by confocal micros-
copy and flow cytometry. The cells were incubated with 
agglutinin 1 (FITC-UEA-1; Sigma Deisenhofen, Ger-
many) and 1, 19-dioctadecyl-3, 3,3939-tetramethylindo-
car-bocyanine perchlorate (DiI)-labeled acetylated low 
density lipoprotein (Dil-Ac-LDL) as described previously 
[18]. Incorporation of DiI-Ac-LDL and binding of FITC-
UEA-1 were detected under confocal microscope (Leica 
Microsystems GmbH, Germany). Cells with double posi-
tive staining of DiI-Ac-LDL and UEA-1 were identified as 
EPCs. The phenotypes of EPCs were analyzed for surface 
expression of CD34, CD133 and VEGFR-2 (all antibod-
ies were purchased from MiltenyiBiotec, Bergisch, Ger-
many). The third or fourth passages of EPCs were used.
MiRNA expression profiles
Total RNA was extracted from EPCs using Trizol reagent 
(Invitrogen, CA, USA) according to the manufacturer’s 
instructions. MiRNA expression profiling was performed 
using a miRNA microarray analysis and miRNA array 
probes (LC Sciences) according to previous methods [19, 
20]. For each sample, triplicates were analyzed and signif-
icant differences between DVT and healthy controls for a 
given detectable miRNA signal were calculated. The ratio 
of the two sets of detected signals (log2 transformed, bal-
anced) and the P values for the t-test were calculated. The 
differentially detected signals with P < 0.01 were analyzed 
(Table 2).
MiRNA quantitative real time RT‑PCR analysis
Quantitative real time PCR was carried out using a 
Roche Light Cycler 480 (Roche, Switzerland), miRNA 
Qqcr Quantitation Kit (GenePharma, Shanghai, China), 
and 200 ng total RNA. RNA was transcribed into cDNA 
Synthesis Kit (Thermo Scientific, MA, USA). Expression 
of the U6 RNA was assessed as an internal control.
Agomir and antagomir transfection
To overexpress and knockdown miR-483-3p, agomir 
and antagomir of miR-483-3p were transfected into 
EPCs using Lipofectamine 3000 (Invitrogen, CA, USA) 






Age, years (mean, SD) 55.4 ± 11.6 57.1 ± 13.2
Gender, females/males 7/6 7/6
Hypertension 0 0
Diabetes mellitus 0 0
Other chronic diseases 0 0
Page 3 of 14Kong et al. J Transl Med  (2016) 14:23 
according to the manufacturer’s instructions. Cells were 
collected at 48 h after transfection, and the expression of 
miRNA was confirmed by real time RT-PCR.
Migration assay
Migration assay was performed in a transwell system as 
described previously. EPCs (2  ×  105 cells) were resus-
pended in serum-free EBM-2 medium and seeded on 
the upper chamber. The lower chamber was filled with 
EBM-2 medium supplemented with 20  % FBS. After 
incubation at 37  °C, 5  % CO2 for 24  h, the cells were 
stained with hematoxylin and the cell number in each 
well was counted in three randomly picked fields (200× 
magnification) under a light microscope. All the experi-
ments were performed in triplicate.
Tube formation assay
In vitro matrigel tube formation assay was performed 
to determine the angiogenic activity of EPCs as previ-
ously described [18]. Briefly, EPCs (5  ×  104 cells) were 
Table 2 The primers of target sequences
Gene name Primer usage Sequence (5′–3′)
hsa-miR-199a-3p RT primer GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACCTGCCC
Forward primer GGTGTCACTCCTCTCCTCC
Reverse primer CAGTGCGTGTCGTGGA
hsa-let-7e-5p RT primer GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACAACTAT
Forward primer GGGGTGAGGTAGGAGGTTGT
Reverse primer GTGCGTGTCGTGGAGTCG
hsa-miR-483-3p RT primer GTCGTATCCAGTGCGTGTCGTGGAGTCGGCAATTGCACTGGATACGACAAGACG
Forward primer GGTGTCACTCCTCTCCTCC
Reverse primer CAGTGCGTGTCGTGGA
U6 (human) RT primer CGCTTCACGAATTTGCGTGTCAT
Forward primer GCTTCGGCAGCACATATACTAAAAT
Reverse primer CGCTTCACGAATTTGCGTGTCAT
hsa-miR-199a-3p Agomir: sense ACAGUAGUCUGCACAUUGGUUA
Agomir: antisense ACCAAUGUGCAGACUACUGUUU
Antagomir: sense UAACCAAUGUGCAGACUACUGU
hsa-let-7e-5p Agomir: sense UGAGGUAGGAGGUUGUAUAGUU
Agomir: antisense CUAUACAACCUCCUACCUCAUU
Antagomir: sense AACUAUACAACCUCCUACCUCA
hsa-miR-483-3p Agomir: sense UCACUCCUCUCCUCCCGUCUU
Agomir: antisense GACGGGAGGAGAGGAGUGAUU
Antagomir: sense AAGACGGGAGGAGAGGAGUGA
rno-miR-483-3p Overexpression GGAUCCGCACUCCUCCCCUCCCGUCUUGUCUGAGAAACAAGACGGAAGGAAACGUCA 
CUUUUUUGAAUUC
rno-miR-483-3p sponge Sponge GGAUCCACAAGACGGGCCCGAGGAGUGCGAUACAAGACGGGCCCGAGGAGUGACCGGUAC 
AAGACGGGCCCGAGGAGUGUCACACAAGACGGGCCCGAGGAGUGUUUUUUGAAUUC
rno-miR-483-3p Forward primer GCTGACTCACTCCTCCCCTC
Reverse primer TATGGTTGTTCACGACTCCTTCAC
U6 (rat) Forward primer ATTGGAACGATACAGAGAAGATT
Reverse primer GGAACGCTTCACGAATTTG
SRF (human) Forward primer GAGATCGGTATGGTGGTCGG
Reverse primer GTCAGCGTGGACAGCTCATA
SRF siRNA    (human) Sense GCAUCAUGAAGAAGGCCUAUU
Anti-sense UAGGCCUUCUUCAUGAUGCUU
β-actin (human) Forward primer ACATCCGCAAAGACCTGTAC
Reverse primer GCCATGCCAATCTCATCTTG
SRF (rat) Forward primer ACCAGCTTCACTCTCATGCC
Reverse primer TGCATGGGGACTAGGGTACA
β-actin (rat) Forward primer ACCCGCGAGTACAACCTTC
Reverse primer ATGCCGTGTTCAATGGGGTA
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transfected with miR-483-3p agomir or antagomir and 
then seeded onto matrigel coated 48-well plate, and 
tubular structures of EPCs in the matrigel were evalu-
ated under microscope after 24 h incubation. To quantify 
the length of newly formed tubes, six random phase con-
trast photos per well were taken, and the length of each 
tube was measured using Image J software. Tube length 
obtained from miR-483-3p antagomir transfected cells 
was set to 100.
Apoptosis analysis by flow cytometry
EPCs were stained with annexin V and propidium iodide 
(PI) (eBioscience, CA, USA), and analyzed by flow 
cytometry as previously described [18].
Luciferase assays
The pMIR-SRF-3′ UTR plasmid containing the putative 
binding site of the SRF 3′UTR downstream of the firefly 
luciferase gene was generated by cloning and inserting of 
a 395 bp sequence located at 3′UTR downstream into the 
SpeI and HindIII sites of the pMIR-REPORT Luciferase 
vector (Ambion, TX, USA). For luciferase activity meas-
urement, HEK293 T cells were grown in 24-well plates 
until 60–70 % confluence and co-transfected with 100 ng 
Luciferase plasmid and 50 ng Renilla plasmid (Ambion) 
as a control for transfection efficiency, along with 650 ng 
miR-483-3p agomir or antagomir or negative control. 
The activity of Luciferase and Renilla was assessed after 
48 h with the Dual Luciferase Reporter 1000 Assay Sys-
tem (Promega, WI, USA).
Western blot analysis
EPCs were lysed in RIPA buffer followed by high-speed 
centrifugation. Cellular proteins were quantified using 
bicinchoninic acid, separated by sodium dodecyl sulfate–
polyacrylamide gel electrophoresis and transferred onto 
polyvinylidenedifluoride membranes. After blocking, the 
membranes were incubated with the antibody for serum 
response factor (SRF) monoclonal (Cell Signaling Tech-
nology, MA, USA) or Actin (Sigma, MO, USA). Next the 
membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies and protein bands were 
detected with SuperSignal West Pico Chemiluminescent 
Substrate (Pierce, Rockford, IL) on x-ray films (Kodak, 
Tokyo, Japan).
Lentivirus, vector production and cells transduction
The lentivirus, vector production and cell transduction 
were performed as previously described [21–23]. Par-
tial pre-miR-483 sequences flanked by EcoRI and AgeI 
restriction site were constructed into the H1 promoter 
of lentivirus infectious virions pGLV3-H1-GFP-Puro 
(GenePharma, Shanghai, China). EPCs were infected 
with the viruses and selected in the presence of 5 μg/
ml puromycin (Sigma), and the green fluorescent pro-
tein (GFP) signal of the infected cells was detected 
under microscope, and the expression of the miR-483 
cluster in EPCs was measured by quantitative real-
time PCR. To generate miR-483-3p sponge lentivirus 
virion, the sequences to miR-483-3p with mismatches 
at position 9–12 were constructed into the pGLV3-
H1-GFP-Puro lentivirus infectious virions and used to 
infect EPCs.
Rat EPCs isolation
Male Sprague–Dawley (SD) rats weighted 300  g were 
purchased from SLAC Experimental Animal Company 
(Shanghai, China). Isolation of rat EPCs was performed 
as previously described [7, 15, 24]. Bone marrow was 
harvested from both femurs and tibias of SD rats. Density 
gradient centrifugation with Ficoll-paque (GE Health-
care, Piscataway, NJ, USA) was used to isolate mononu-
clear cells. The cells were seeded into flask pre-coated 
with human fibronectin (Sigma) and cultured in EGM-
2-MV (Lonza, MD, USA) medium at 37 °C in a 5 % CO2 
incubator. After 4 days, non-adherent cells were removed 
by PBS washing, and the adherent cells were cultured 
with fresh medium. The third and fourth generations of 
EPCs were used.
Rat model of venous thrombosis
The animal protocol was approved by the Institutional 
Animal Care and Use Committee of Soochow Uni-
versity. SD rats were purchased from the Experiment 
Animal Center of Soochow University. The rats were 
anesthetized by intraperitoneal injection of 10 % chloral 
hydrate. A midline laparotomy was performed. The infra-
renal inferior vena cava (IVC) was exposed and all side 
branches were ligated with 7-0 Prolene suture. The pos-
terior venous branches were blocked by  electric coagu-
lation. A 7-0 Prolene suture was tied down on the IVC 
just below the left renal vein. At the same time, a micro-
vascular clamp was attached to the confluence of iliac 
veins for 15 min to block the blood flow and induced the 
thrombus in IVC. The skin was sutured and the rats were 
allowed to recover after the surgery. Then the rats were 
divided into four groups for cell transplantion via tail 
intravenous injection (n =  10): (A) blank control group 
(blank control) received same volume of cell culture 
medium; (B) EPCs/pGLV3-H1-GFP-Puro vector group 
(EPCs/vector) received 1.0 × 106 EPCs transfected with 
pGLV3-H1-GFP-Puro control vector; (C) EPCs/pGLV3-
H1- GFP-Puro-miR-483-3p group (EPCs/miR- 483-3p) 
received 1.0  ×  106 EPCs transfected with pGLV3-H1-
GFP-Puro-miR-483-3p; (D) EPCs/pGLV3-H1-GFP-Puro-
miR-483-3p sponge group (EPCs/miR-483-3p sponge) 
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received 1.0  ×  106 EPCs transfected with pGLV3-H1-
GFP-Puro-miR-483-3p sponge.
Histology
Seven days after the injection of either EPCs or control 
medium, the animals were sacrificed and IVC segments 
containing the thrombus were carefully harvested, and 
excess blood was absorbed with filter paper. The thrombi 
were weighed and embedded in optimal cutting tem-
perature (OCT) media and flash-frozen in a −80  °C. 
Five micrometer cryosections were cut for histological 
analyses and a confocal microscope (Leica Microsystems) 
was used to analyze the homing of EPCs. The remaining 
samples were used for the analysis of thrombus organiza-
tion and recanalization with hematoxylin and eosin (HE) 
staining.
DSA
IVC venography was performed with digital subtract 
angiography (DSA, GE Innova 3100, USA) by injecting 
contrast media into rat caudal vein or femoral vein to 
determine the recanalization and resolution of thrombus 
in vivo.
Statistical analyses
All statistical analyses were carried out using SPSS v21 
(SPSS, Chicago, IL). Data are presented as mean ± SEM. 
Student’s t-test or one way ANOVA followed by Least 
Significant Difference test was used to compare the dif-
ferences between or among the groups. Univariate com-
parisons of two independent groups were done using the 
Mann–Whitney-U test. Comparisons of multiple groups 
were performed with the Kruskal–Wallis test. P  <  0.05 
was considered significant.
Results
The upregulation of miR‑483‑3p in EPCs from patients 
with DVT
EPCs were isolated from both DVT patients (n = 3) and 
healthy donors (n = 3), and the expression of miRNA was 
determined using a microarray assay (Additional file  1: 
Figure S1). Three miRNAs (upregulated miR-483 and 
downregulated let-7e and miR-199a) exhibited signifi-
cantly fold changes (Fig. 1). To further confirm the accu-
racy of the microarray data, we performed quantitative 
RT-PCR to evaluate the expression of miRNA in DVT 
(n = 3) and healthy control (n = 3). Our results showed 
that the expression of miR-483-3p was significantly 
upregulated (Fig. 1, fivefold increase, P < 0.05), indicating 
the potential role of miR-483-3p in DVT.
EPCs colony exhibited a round morphology and 
formed a central cluster after 3 days of culture (Fig. 2Aa). 
An elongated spindle-shaped morphology was found in 
early EPCs after seventh day of culture (Fig. 2Ab). FACS 
analysis showed the expression of CD34, CD133 and 
VEGFR-2 on EPCs at day 14 (Fig. 2B). EPCs were further 
characterized by double staining with functional marker 
FITC-UEA-I and Dil-ac-LDL (Fig. 2C).
MiR-483-3p decreased the migration, tube formation 
and increased the apoptosis of EPCs.
To clarify the role of miR-483-3p in EPCs, we employed 
miR-483-3p agomir and antagomir to overexpress and 
inhibit miR-483-3p in EPCs. EPCs transfected with miR-
483-3p agomir displayed decreased ability of migration 
(Fig. 3a), tube formation (Fig. 3b) and increased apopto-
sis (Fig.  3c). EPCs transfected with miR-483-3p antago-
mir exhibited opposite behaviors on cell migration, tube 
formation and apoptosis (Fig. 3a–c).
SRF is the target gene of miR‑483‑3p in EPCs
Based on multiple databases (TargetScan, Microcosm 
Targets and RNA22-HAS), SRF was predicted to have 
a putative miR-483-3p binding sites within its 3′UTR 
(Fig. 4a, b).
To confirm that SRF is a direct target of miR-483-3p, we 
performed luciferase reporter assay and found decreased 
luciferase activity after a 395  bp region of 3′-UTR SRF 
was cloned into the luciferase report vector (Fig. 4c, d).
To confirm the ability of miR-483-3p to inhibit SRF 
expression, we transfected EPCs with miR-483-3p agomir 
and antagomir. EPCs transfected with miR-483-3p ago-
mir exhibited significantly decreased SRF protein level 
while EPCs tranfected with miR-483-3p antagomir exhib-
ited increased SRF protein level (Fig. 4e). As expected, we 
detected reduced protein level of SRF in EPCs after SRF 
siRNA transfection (Fig. 4f ).
In addition, DVT patients (n = 10) and healthy control 
subjects (n = 10) were included to verify the upregulation 
Fig. 1 Differentially expressed miRNAs in EPCs from healthy control 
and patients with DVT by microarray (Arraystar, human miRNA 
18.0 chip). Three aberrantly expressed miRNAs were identified by 
quantitative real-time PCR. Data are expressed as mean ± SEM (n = 3, 
**P < 0.01 vs. health control)
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of miR-483-3p in EPCs from DVT patients by quan-
titative real-time PCR (Fig.  4g). Western blot analysis 
showed decreased protein level of SRF in DVT patients 
(n = 10) compared to healthy controls (n = 10) (Fig. 4h).
MiR‑483‑3p regulates EPCs function by targeting SRF
To explore the role of SRF in EPCs function, EPCs were 
transfected with SRF siRNA. EPCs transfected with SRF 
siRNA exhibited decreased cell migration (Fig. 5a), tube 
formation (Fig.  5b) and increased apoptosis (Fig.  5c), 
compared to EPCs transfected with vehicle controls. 
To further confirm that miR-483-3p modulated EPCs 
function by targeting SRF, we performed rescue experi-
ments by co-transfection of miR-483-3p agomir and SRF 
expression vector in EPCs, and EPCs showed similar 
trend of cell migration, tube formation and apoptosis as 
controls (Fig. 5a–c).
Knockdown of miR‑483‑3P in EPCs via lentivirus‑mediated 
miR‑483‑3p sponge
We constructed a miR-483-3p sponge consisted of a 
decoy vector containing tandem repeated miRNA bind-
ing sites downstream of GFP (Fig.  6a). Binding sites for 
miR-483-3p were complementary in the seed region 
with a bulge at positions 9–12 to prevent RNA interfer-
ence-type cleavage and degradation of the sponge RNA 
constructed into the pGLV3-H1-GFP-Puro lentivirus 
infectious virions (Fig.  6b). EPCs were infected with 
Fig. 2 Isolation and characterization of EPCs. A On day 3 (a), EPCs colony exhibited a round morphology and formed a central cluster. On day 7 
(b), EPC exhibited spindle-shaped cell radiating from the central cluster (×100). B FACS analysis of the cell surface markers of EPCs at day 14 (CD34, 
CD133, VEGFR-2). Data are expressed as mean ± SEM. C Staining of DiI-Ac-LDL, FITC-UEA-1, and merged image of double staining of FITC-UEA-1 
and DiI-Ac-LDL (×400)
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Fig. 3 miR-483-3p regulates migration, tube formation, and apoptosis of EPCs. EPCs were transfected with miR-483-3p agomir or antagomir or 
negative control. a Migrated cell counting (×200). **P < 0.01 vs. negative control, ***P < 0.001 vs. negative control (n = 3). b Relative tube number 
and length (×100). **P < 0.01 vs. negative control, ***P < 0.001 vs. negative control (n = 3). c Cell apoptosis was determined by annexin V/PI stain-
ing. **P < 0.01 vs. negative control ***P < 0.001 vs. negative control (n = 3). All data are expressed as mean ± SEM
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lentivirus-mediated vector control, miR-483-3p and 
miR-483-3p sponge, and the expression of the miR-483 
cluster was measured by quantitative real-time PCR. 
MiR-483-3p sponge lentivirus virions totally silenced the 
expression of miR-483-3p (Fig. 6c). Western blot analysis 
showed that SRF protein level was significantly increased 
after miR-483-3p sponge treatment (Fig. 6d).
MiR‑483‑3p inhibited EPCs homing
A rat model of DVT was established by inferior vena cava 
ligation. EPCs transfected with pGLV3-H1-GFP-Puro-
miR-483-3p were intravenously administrated into the 
rats. Cyrosections of thrombus were prepared on day 7 
after EPCs transplantation. EPCs were found to home 
and locate around the thrombus after transplantation. 
Fig. 5 miR-483-3p and SRF functionally regulate EPCs function. a Decreased EPCs migration in EPCs transfected with SRF-siRNA. (n = 3, **P < 0.01 
vs. negative control; ##P < 0.01 vs. miR-483-3p agomir + SRF). b Decreased tube number and length in EPCs transfected with SRF-siRNA (×100) 
(n = 3, **P < 0.01vs NC; ##P < 0.01 vs. miR-483-3p agomir + SRF). c Increased EPCs apoptosis after SRF-siRNA transfection. (n = 3, *P < 0.05 vs. nega-
tive control; **P < 0.01 vs. negative control; ##P < 0.01 vs. miR-483-3p agomir + SRF). Each bar represents mean values ± SEM
(See figure on previous page.) 
Fig. 4 SRF is a validated target of miR-483-3p. a SRF is a putative target of miR-483-3p. Putative binding sites of miR-483-3p in the SRF 3′UTR 
predicted by TargetScan among different mammalian species. b Putative binding sites of hsa-miR-483-3p in the human SRF 3′UTR (white sequences) 
predicted by TargetScan. c Schematic graph of the constructed reporter plasmid containing putative binding sites of hsa-miR-483-3p in the SRF 
3′UTR. SRF-3′UTR mut indicates the SRF-3′UTR with mutation in miR-483-3P-binding site. The mutated nucleotides in SRF-3′UTR fragments are 
underlined. d Dual luciferase report assays were performed on HEK 293 T cells. Each bar represents mean values ± SEM (n = 3, **P < 0.01). e The 
protein level of SRF in EPC transfected with miR-483-3p agomir and antagomir. Each bar represents mean values ± SEM (n = 3, *P < 0.05 vs. nega-
tive control; **P < 0.01 vs. negative control). f The protein level of SRF in EPC transfected with miR-483-3p agomir and SRF, SRF siRNA. Each bar 
represents mean values ± SEM (n = 3, **P < 0.01 vs. negative control). g miR-483-3p expression was measured in healthy control and patients with 
DVT by quantitative real-time PCR. Data are expressed as mean ± SEM (n = 10, ***P < 0.01 vs. health control). h The protein level of SRF in patients 
with DVT and health control. Each bar represents mean values ± SEM (n = 10, *P < 0.05 vs. health control)
Page 10 of 14Kong et al. J Transl Med  (2016) 14:23 
Significantly increased EPCs homing was found in the 
rats infused with EPCs/miR-483-3p sponge group com-
pared to EPCs/miR-483-3p group on day 7 after EPCs 
transplantation (Fig. 7a, b).
Inhibition of miR‑483‑3p promoted thrombus 
recanalization and resolution
HE staining showed that nucleated cells, including mono-
cytes, endothelial cells and neutrophil granulocytes entered 
into the perimeter of the thrombus on day 7. The red blood 
cells, platelets and fibrin were dried red in the center of 
thrombus. There were more nucleated cells and channels in 
EPCs/vector and EPCs/miR-483-3p sponge group than in 
control group on day 7 (Fig. 7c). In addition, miR-483-3p 
sponge decreased the weight of thrombus (IVC + throm-
bus at harvest). Compared with control group, the weight of 
thrombus was similar to EPCs/miR-483-3p group, whereas 
significant decrease of thrombus weight was observed in 
EPCs/vector and EPCs/miR-483-3p sponge groups on day 
7 after transplantation. Furthermore, the thrombus weight 
of EPCs/miR-483-3p sponge group was even lower than 
that of EPCs/vector group (18.7 ± 6.1 vs. 30.6 ± 8.3 mg on 
day 7, P < 0.05, Fig. 7d).
DSA has been widely accepted as the reference stand-
ard for DVT diagnosis and therefore we evaluated the 
thrombus recanalization and resolution in  vivo by using 
DSA. A contrast agent was injected into the rats to illus-
trate the vessel. We observed significantly increased 
thrombus recanalization and resolution in rats trans-
planted with miR-483-3p sponge transfected EPCs com-
pared to miR-483-3p transfected EPCs on day 7 (Fig. 7e, f ).
Discussion
In the present study, we reported several important 
findings on the role of miR-483-3p in EPCs. First, miR-
483-3p expression was increased in EPCs derived from 
patients with DVT. Overexpression of miR-483-3p 
decreased migration and angiogenic potential of EPCs 
while increased apoptosis of EPCs. Moreover, we identi-
fied SRF as the target of miR-483-3p in EPCs. The migra-
tion, angiogenic potential and apoptosis of EPCs were 
positively regulated by SRF, and the suppression of SRF 
by miR-483-3p contributed to the effects of miR-483-3p 
on EPCs function. In addition, we established a rat 
model of vein thrombosis and observed that transplan-
tation with EPCs transfected with miR-483-3p displayed 
increased homing ability and improved the thrombus 
recanalization and resolution in vivo. Taken together, our 
data suggest that miR-483-3p plays an important role in 
EPCs dysfunction, and upregulated miR-483-3p in EPCs 
Fig. 6 miR-483-3p sponge rescues SRF expression in EPCs. a Schematic graph of miRNA construction. b Binding sites of miR-483-3p sponge. c 
The relative expression of miR-483-3p after infection with lenti-vector control, lenti-483-3p and lenti-483-3p sponge. The relative expression data 
were normalized to the amount of U6, and expressed as mean ± SEM (n = 3, *P < 0.05 vs. lenti-vector; ***P < 0.001 vs. lenti-vector; ###P < 0.001 vs. 
lenti-483-3p). d SRF protein level was significantly increased after miR-483-3p sponge treatment. Each bar represents mean values ± SEM (n = 3, 
*P < 0.05 vs. lenti-vector; **P < 0.01 vs. lenti-vector)
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from DVT contributes to impaired EPCs function, which 
is likely due to decreased SRF.
Vein thrombi resolution is a complex and spontane-
ous process that requires the orchestration of different 
cells [25]. Three main steps include the infiltration of 
inflammatory cell into the thrombus, tissue remodeling 
and angiogenesis. The vascularization of the thrombus 
is an early and important event on the efficacy of throm-
bus resolution [25]. Growing evidences have suggested 
that bone marrow-derived EPCs are recruited into the 
thrombus and involved in the thrombus organization 
and resolution [8, 26]. Several studies have reported the 
importance of EPCs in injured vessels repairmen and 
ischemic tissues revascularization [27]. We previously 
demonstrated that bone marrow-derived EPCs trans-
plantation altered the vein microenvironment in a rat 
model of chronic vein thrombosis [28].
When DVT occurs, EPCs could home and migrate to 
the sites of neovascularization, increase new blood ves-
sel formation in the injured site [29], and secrete a variety 
of vasoactive and angiogenic factors to improve angio-
genesis thrombus resolution [25, 30]. In addition, EPCs 
have the potential to protect differentiated endothelial 
cells from apoptosis and to preserve their angiogenic 
capacity under conditions of oxidative stress [31]. The 
proposed mechanisms of EPCs in thrombus resolution 
are as follows. EPCs can home and integrate into the 
site of the injured vessels and thrombi and participate in 
orchestrating the angiogenesis process. EPCs residing in 
the thrombi can release a source of paracrine pro-angio-
genic factors to induce vascularization. Moreover, EPCs 
produce proteinases to break down thrombi and secrete 
other factors to interact with platelets to prevent the 
apoptosis of mature endothelial cells and the formation 
of new thrombosis [32].
MiRNAs have been shown to play key roles in vascu-
lar development, homeostasis, function, disease and 
regeneration [33]. In particular, miRNAs have impact 
on angiogenesis and modulate the behavior of EPCs [15, 
34, 35]. Therefore, we proposed that miRNA modified 
EPCs could improve the efficacy of EPCs in the thrombus 
resolution and recanalization. However, the potential of 
EPCs-mediated cancer initiation should be paid attention 
[36].
MiR-483-3p is located within the insulin growth fac-
tor (IGF2) locus at chromosome 11p15.5 and implicated 
in various human cancers including colon, breast, liver 
cancers and squamous cell carcinomas [37, 38]. IGF2 is 
involved in angiogenesis through the regulation of the 
IGF/IGF2R system, and miR-483-3p was an intronic 
miRNA within IGF2. Until now, the exact role of miR-
483-3p in the function of EPCs has not been determined 
yet. In the present study, miR-483-5p emerges as a novel 
angio-miR that negatively regulates angiogenesis. By 
in vitro tube formation assay, we demonstrated that miR-
483-3p modulated angiogenic potential of EPCs. Moreo-
ver, we found that miR-483-3p regulated the migration 
and apoptosis of EPCs.
To elaborate putative mechanism by which miR-483-3p 
regulates EPCs function, we employed bioinformat-
ics tool and molecular biology method to identify tar-
get gene. Our results suggested that SRF could be the 
potential target of miR-483-3p. SRF is involved in the 
regulation of multiple genes implicated in cell growth, 
proliferation, migration, apoptosis, cytoskeletal organiza-
tion, energy metabolism and myogenesis [39, 40]. More-
over, SRF is important for the appropriate expression 
of structural proteins such as β-actin, VE-cadherin and 
several integrins in endothelial cells, and changed expres-
sion of SRF could lead to defective vascular morphogen-
esis [41]. In addition, SRF was reported to mediate FGF 
signaling in tracheal terminal branching and VEGF/FGF 
signaling in sprouting angiogenesis [42]. Indeed, previ-
ous study reported that miR-483-5p directly targeted SRF 
in human umbilical vein endothelial cells and inhibited 
angiogenesis in  vitro [43]. Therefore, our present study 
extended previous findings on  miR-483-SRF pathway 
from endothelial cells to EPCs.
There are some limitations in this study. Our results con-
firmed that SRF was a target of miR-483-3p and the sup-
pression of SRF by miR-483-3p was involved in the effects 
of miR-483-3p on EPCs function. However, additional 
target genes are likely to participate in the anti-angiogenic 
effect of miR-483-3p, which remain to be investigated in 
(See figure on previous page.) 
Fig. 7 MiR-483-3p decreases EPCs homing, thrombus recanalization and resolution. a Representative images of recruitment of GFP-positive EPCs 
in the deep venous thrombosis (×200). b Quantification of GFP-positive EPCs in thrombus sections. Data are expressed as mean ± SEM (n = 10, 
**P < 0.01 vs. EPCs/vector; ***P < 0.001 vs. EPCs/vector; ###P < 0.001 vs. EPCs/miR-483-3p). c Hematoxylin and eosin (HE) staining of thrombus Sects. 
(200× magnification). T means thrombus and VW indicates venous wall. d Weight of the venous thrombi at day 7 post the transplantation. Data 
are expressed as mean ± SEM (n = 10, **P < 0.01 vs. blank control; ***P < 0.001 vs. blank control; ##P < 0.01 vs. EPCs/vector). e Significantly increase 
of thrombus recanalization and resolution was found in rats transplanted with EPCs transfected with miR- 483-3p sponge compared to EPCs trans-
fected miR-483-3p on Day 7. f The recanalization of thrombus was quantified with Image J software by the area ratio of contrast agent in vascular 
with thrombosis. Data are expressed as mean ± SEM (n = 10, **P < 0.01 vs. blank control; ***P < 0.001 vs. blank control). Comparison among multi-
ple groups was performed by one-way ANOVA followed by Least Significant Difference test
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the near future. Furthermore, the criteria of EPCs are still 
controversial. In this study, we used adherent PBMCs with 
the features of DiI-ac-LDL endocytosis and UEA-I expres-
sion binding, and the cells also showed the expression of 
CD34, CD133 and VEGFR-2. These EPCs have been shown 
to self-renew and form tube-like structures in  vitro, and 
there might be several cell subpopulations in these EPCs.
Conclusions
In conclusion, this study shows that miR-483-3p is upreg-
ulated in EPCs from DVT patients and it impairs EPCs 
function via its target SRF. Furthermore, the application 
of EPCs transfected with miR-483-3p inhibitor into the 
vein thrombosis rat model improved the thrombus reca-
nalization and resolution. These data suggest that miR-
483-3p might be employed as a therapeutic target in the 
treatment of thrombus in the clinical practice.
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